<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02113163</url>
  </required_header>
  <id_info>
    <org_study_id>TP-101-CS01</org_study_id>
    <nct_id>NCT02113163</nct_id>
  </id_info>
  <brief_title>PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA</brief_title>
  <official_title>An Open-label, Single and Repeat Single Ascending Dose Escalation Study to Compare the Pharmacokinetics of Metformin Eicosapentaenoate With Metformin Hydrochloride and Icosapent Ethyl Following Oral Administration to Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thetis Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thetis Pharmaceuticals LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to contrast the pharmacokinetic profiles of metformin&#xD;
      and EPA delivered separately as co-administered products (metformin hydrochloride or&#xD;
      Glucophage and icosapent ethyl or Vascepa) and together as the solid dose form (metformin&#xD;
      eicosapentaenoate or TP-101) under fasted and fed conditions. A secondary objective is to&#xD;
      evaluate the safety and tolerability of single and repeat single doses of TP-101.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC following single and repeat single oral administration of metformin eicosapentaenoate, metformin hydrochloride and Vascepa</measure>
    <time_frame>PK samples at 0, 0.5, 1, 2, 4, 8, and 12 hours following drug administration</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Diabetes Mellitus, Non-Insulin-Dependent</condition>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>Cohort A - Low Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin Eicosapentaenoate 1500 mg or Metformin HCl 500 mg and Vascepa 1000 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B - High Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin Eicosapentaenoate 3000 mg or Metformin HCl 1000 mg and Vascepa 2000 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Eicosapentaenoate</intervention_name>
    <arm_group_label>Cohort A - Low Dose</arm_group_label>
    <arm_group_label>Cohort B - High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin HCl and Vascepa</intervention_name>
    <arm_group_label>Cohort A - Low Dose</arm_group_label>
    <arm_group_label>Cohort B - High Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent executed prior to protocol screening assessments;&#xD;
&#xD;
          -  Men or women 18 to 65 years of age, inclusive (Women may be surgically sterile via&#xD;
             tubal ligation, bilateral oophorectomy or hysterectomy or who are postmenopausal for&#xD;
             &gt;1 year. Women who are of childbearing potential must agree to practice adequate&#xD;
             contraception one month before the first dose of study medication and up to Day 16 of&#xD;
             the study. Adequate contraception may include, but is not limited to, abstinence,&#xD;
             monogamous relationship with vasectomized partner, barrier methods such as condoms or&#xD;
             diaphragms with spermicide or foam, intrauterine devices, and licensed hormonal&#xD;
             methods.);&#xD;
&#xD;
          -  No history of chronic diseases, except for subjects with well-controlled hypertension&#xD;
             or well-controlled hyperlipidemia;&#xD;
&#xD;
          -  BMI â‰¤30kg/m2;&#xD;
&#xD;
          -  No significant medical history including diabetes or hypertension complicated by&#xD;
             hyperlipidemia (metabolic syndrome);&#xD;
&#xD;
          -  Negative urine drug and alcohol tests at Screening; and,&#xD;
&#xD;
          -  No metformin or omega-3 products within 2 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Abnormal findings on physical examination, EKG, vital signs, and clinical laboratory&#xD;
             testing, in the judgment of the investigator;&#xD;
&#xD;
          -  Allergies to fish or shellfish;&#xD;
&#xD;
          -  Impaired renal function (calculated eGFR &lt;60 mL/min);&#xD;
&#xD;
          -  Abnormal laboratory values for T3, T4 and TSH at the Screening Visit;&#xD;
&#xD;
          -  Aspartate aminotransferase/alanine aminotransferase (AST/ALT) &gt;2x upper limits of&#xD;
             normal (ULN) or serum bilirubin &gt;1.5 mg/dL;&#xD;
&#xD;
          -  Requirement of prescription medication within 14 days of the Screening Visit, with the&#xD;
             exception of prescription medications for the prevention of pregnancy, anti&#xD;
             hypertensives for hypertension, or statins for hyperlipidemia. Doses of one or two&#xD;
             anti-hypertensives and/or a statin must be stable for &gt;1 month;&#xD;
&#xD;
          -  Normal doses of over-the-counter medications, including vitamins are allowed but not&#xD;
             within 3 days of Visit 2 (first day of dosing);&#xD;
&#xD;
          -  Current or history of abuse of alcohol or illicit drugs within the preceding year to&#xD;
             the Screening Visit;&#xD;
&#xD;
          -  Participation in a dietary modification or an intensive weight loss program;&#xD;
&#xD;
          -  Participation in another clinical trial of an investigational product within 3 months&#xD;
             prior to the Screening Visit;&#xD;
&#xD;
          -  Smokers (use of tobacco in the past 3 months); or,&#xD;
&#xD;
          -  Donation or loss of 400 mL blood or more in the last 8 weeks.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lauren Harrington, RN</last_name>
    <phone>225-763-2699</phone>
    <email>Lauren.Harrington@pbrc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tance Sonnier</last_name>
    <phone>225-763-2623</phone>
    <email>Tance.Sonnier@pbrc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Frank Greenway, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>April 10, 2014</study_first_submitted>
  <study_first_submitted_qc>April 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2014</study_first_posted>
  <last_update_submitted>April 10, 2014</last_update_submitted>
  <last_update_submitted_qc>April 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>T2DM</keyword>
  <keyword>hypertriglyceridemia</keyword>
  <keyword>severe hypertriglyceridemia</keyword>
  <keyword>dyslipidemia</keyword>
  <keyword>triglycerides</keyword>
  <keyword>lipids</keyword>
  <keyword>omega-3 fatty acids</keyword>
  <keyword>EPA</keyword>
  <keyword>ethyl-EPA</keyword>
  <keyword>Metformin</keyword>
  <keyword>Glucophage</keyword>
  <keyword>Lovaza</keyword>
  <keyword>Vascepa</keyword>
  <keyword>Epanova</keyword>
  <keyword>Astra Zeneca</keyword>
  <keyword>Amarin</keyword>
  <keyword>GSK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Eicosapentaenoic acid ethyl ester</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

